Expert Analysis

Clinical Update on Metabolic Complications and Adverse Events

Source: CCO Independent Conference Coverage of the 2008 Conference on Retroviruses and Opportunistic Infections*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Clinical Update on Metabolic Complications and Adverse Events

Faculty:

Andrew Carr, MBBS, MD, FRACP, FRCP
Judith S. Currier, MD, MSc
William G. Powderly, MD

CME CREDIT INFORMATION

Release Date: 04/04/08

Expiration Date: 04/03/09

Physicians: maximum of 0.5 AMA PRA Category 1 Credits™

Registered Nurses: 0.7 Nursing CE credits

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Identify new findings on factors associated with increased risk of mortality in HIV-infected populations
Discuss new data on risks of and treatment for body habitus changes
Identify new findings on NRTI-associated increased risk of myocardial infarction

Topics covered include:

All-Cause Mortality in Untreated Patients With CD4+ Cell Counts > 350 cells/mm³
Mortality Risk Markers, Plasma Viremia, and Treatment Interruption
Increased Relative Risk of Myocardial Infarction With Recent Use of Abacavir or Didanosine in D:A:D
Echocardiographic Abnormalities in HIV-Infected Populations
Lipid Changes With Efavirenz, Maraviroc, and Ritonavir 100 mg or 200 mg
Lipoatrophy Reversion With Tenofovir and Lipoatrophy Risk Factors
Continued Tesamorelin Maintains Visceral Fat Losses
Physiologic Growth Hormone Replacement for Visceral Fat
Antiretrovirals and Decreased Bone Mineral Density

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.